No profile data available.
Spruce Biosciences, Inc. (SPRB) is a healthcare company in the additional hormone and metabolic drugs industry, based in South San Francisco, United States, with about 22 full-time employees.
It reported revenue of $4.91 million for fiscal year 2024, down 51.3% from fiscal year 2023, and net income of -$53.04 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $0, down 100.0% from a year before. Its market capitalization was $126.60 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B.
Spruce Biosciences reported $4.91 million in revenue for fiscal year 2024, down 51.3% from $10.09 million in fiscal year 2023. In Q3 2025 revenue was $0.
$126.60 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional hormone and metabolic drugs) include Immix Biopharma, Inc. (IMMX), Arbutus Biopharma Corporation (ABUS), Rezolute, Inc. (RZLT), International Isotopes Inc. (INIS).